HONG KONG SAR - Media OutReach - 20 June 2022 - On 19 June, the technology innovation pharmaceutical company, Grand Pharmaceutical Group Limited (stock code: 0512.HK)’s global innovative product, SIR-Spheres® Y-90 microsphere injection for the treatment of liver malignant tumors, was officially commercialized in Mainland China. An innovative treatment method at the level of “nuclear
Grand Pharma’s Innovative Product for Liver Tumors, Y-90, Is Commercialized in Mainland China, Empowering "Nuclear Power" to The Company’s Performance | 2022-06-20 19:40:00
Investment agreement strengthens the strategic alliance between the two companies while supporting ITM in further developing its radiopharmaceutical pipeline and footprint in Asia Equity investment
SIR-Spheres Y-90 resin microspheres are the first therapeutic radiopharmaceutical approved by the NMPA in 2022 WOBURN, Mass., Feb. 9, 2022 /PRNewswire/ Sirtex Medical ("Sirtex"), a leading